Probiotics: A review of human studies to date and methodological approaches

Microbial Ecology in Health and Disease

Volumn 12, Issue SUPPL. 2, 2000, Pages 10-30

  Pathmakanthan, S ^a   Meance, S ^b   Edwards, C A ^c  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b DANONE RESEARCH   (France)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PROBIOTIC AGENT;

CANCER; CLOSTRIDIUM DIFFICILE; CONSTIPATION; DIARRHEA; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERCHOLESTEROLEMIA; LACTOBACILLUS; LACTOSE INTOLERANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRAVELLER DIARRHEA; URINARY TRACT INFECTION; VAGINA CANDIDIASIS;

EID: 0034527346     PISSN: 0891060X     EISSN: None     Source Type: Journal    
DOI: 10.1080/089106000750060251     Document Type: Review

References (136)

1. Efficiency of various intestinal bacteria in assuming normal functions of enteric flora after association with germ free mice
2. Clostridium difficile enterocolitis cured by rectal infusion of normal faeces
3. Probiotics in human medicine
4. Function of the normal human microflora
5. Lactobacillus acidophilus LA1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria
6. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin
7. Probiotics: Functionality and commercial status
8. Essais explicatifs ou pragmatiques: Le dualisme
9. Scientific concepts of functional foods in Europe: Consensus document
10. Effects of probiotic bacteria on diarrhoea, lipid metabolism, and carcinogenesis: A review of papers published between 1988 and 1998
11. Immunologic effects of yoghurt
12. In ingredients
13. A human Lactobacillus strain (Lactobacillus casei sp GG) promotes recovery from acute diarrhoea in children
14. Oral bacteriotherapy for viral gastroenteritis
15. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus
16. A controlled double-blind study of SF68 strain as a new biological preparation for the treatment of diarrhoea in paediatrics
17. Traitement des diarrhees aigues infantiles: Essai contrôlé de Saccharomyces boulardii
18. A placebo controlled trial of Lactobacillus GG to prevent diarrhoea in undernourished Peruvian children
19. The effect of supplementation with milk fermented by Lactobacillus casei (strain DN-114 001) on acute diarrhoea in children attending day care centres
20. Emploi des ferments lactiques dans la gastro-enterite non bactérienne
21. Controlled trial of orally administered lactobacilli in acute infantile diarrhoea
22. The effects of Bifidobacterium breve administration on campylobacter enteritis
23. Lactobacillus prophylaxis for diarrhoea due to enterotoxigenic Escherichia coli
24. A double-blind, controlled trial of Bioflorin (Streptococcus faecium SF68) in adults with acute diarrhoea due to Vibrio cholerae and enterotoxigenic Escherichia coli
25. A double-blind comparison of two different treatments for acute enteritis in adults
26. Double-blind report on the efficacy of lactic acid producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea in the treatment of acute diarrhoea
27. Efficacité de Saccharomyces boulardii dans le traitement des diarrhées du SIDA
28. Prophylactic efficacy of lactobacilli on travellers diarrhoea
29. Prevention of traveller's diarrhoea by Lactobacillus GG
30. Prophylaxe der Reisediarrhee mit Saccharomyces boulardii
31. Effect of a Lactobacilli preparation on traveller's diarrhoea
32. Lactobacilli to prevent traveller's diarrhoea?
33. Antibiotic-associated diarrhoea
34. Diarrhoea acquired in the hospital
35. Hospital-acquired diarrhoea in adults: A prospective case controlled study in Mexico
36. Essais cliniques contrôlés en double insu de l'ultra-levure lyophilisée. Etude multi-centrique par 25 médecins de 388 cas
37. Prevention of antibiotic-associated diarrhoea by Saccharomyces boulardii: A prospective study
38. Prevention of beta lactam associated diarrhoea by Saccharomyces boulardii compared to placebo
39. Prophylaxis against ampicillin-associated diarrhoea with a Lactobacillus preparation
40. A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxycillin-induced diarrhoea
41. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea
42. Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal effects
43. Effects of supplements of Bifidobacterium longum and Lactobacillus acidophilus on the intestinal microbiota during administration of clindamycin
44. Double-blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea
45. Acquisition of Clostridium difficile by hospitalised patients: Evidence for colonised new admissions as a source of infection
46. Nosocomial acquisition of Clostridium difficile infection
47. Recurrent Clostridium difficile diarrhoea: Characteristics of and risk factors for patients enrolled in a prospective, randomised, double blinded trial
48. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA medical center. 1982-1991
49. Is Clostridium difficile endemic in chronic-care facilities?
50. Recurrence of antibiotic associated colitis: Endogenous persistence of C. difficile during vancomycin therapy
51. Relapse versus reinfection with Clostridium difficile
52. Recurrences of Clostridium difficile diarrhoea not caused by the original infecting organism
53. Pseudomembranous enterocolitis: Mechanism of restoring floral homeostasis
54. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients
55. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG
56. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG
57. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii
58. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease
59. Saccharomyces boulardii for Clostridium difficile associated enteropathies in infants
60. Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain
61. Treatment of Clostridium difficile diarrhoea with brewer's yeast
62. Association of gastric hypoacidity with opportunistic infections in patients with AIDS
63. Efficacité de Saccharomyces boulardii dans le traitement des diarrhees du SIDA
64. Studies on the therapeutic properties of acidophilus milk
65. The effect of acidophilus milk in the treatment of constipation in hospitalised geriatric patients
66. Colonization and faecal enzyme activities after oral Lactobacillus GG administration in elderly nursing home residents
67. Effects of Lactobacillus GG yoghurt on human intestinal microecology in Japanese subjects
68. Clinical experience with the use of the high concentration lactic acid bacteria preparation LP-201 to treat habitual constipation
69. The effect of bifidobacterium cultured milk on the 'regularity' among aged group
70. Investigation of the stool frequency in elderly who are bed ridden and its improvements by ingestion of bifidus yoghurt
71. Effects of fermented-milk administration on defecation and faecal microflora of healthy volunteers
72. Effets du lait fermenté contenant du Bifidobacterium sur le temps de transit colique
73. Effect of Bifidobacterium fermented milk (Bio Strain) on the colonic transit time in healthy humans
74. TM) on the oro-fecal transit time in elderly
75. Treatment of chronic constipation with lactitol sweetened yoghurt supplemented with guar gum and wheat bran in elderly hospital in-patients
76. Does yoghurt enriched with Bifidobacterium longum affect colonic microbiology and faecal metabolites in healthy subjects?
77. Effect of yoghurt and yoghurt supplemented with Bifidobacterium and/or lactulose in healthy persons: A comparative study
78. Vaginal flora in health and disease
79. Is there a role for Lactobacilli in prevention of urogenital and intestinal infections?
80. 2 producing lactobacilli and bacterial vaginosis in pregnant women
81. Ingestion of yoghurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis
82. Lactobacillus GG vaginal suppositories and vaginitis
83. Influence of three day antimicrobial therapy and Lactobacillus vaginal suppositories on recurrence of urinary tract infections
84. Influence of nonfermented dairy products containing bacterial starter cultures on lactose maldigestion in humans
85. Lactose malabsorption from yoghurt, pasteurized yoghurt, sweet acidophilus milk, and cultured milk in lactase deficient individuals
86. Disponibilité du lactose ingéré sous differentes formes de produits laitiers fermentés
87. Health and nutritional benefits from lactic acid bacteria
88. Anticholetrolemic property of Lactobacillus acidophilus yoghurt fed to mature boars
89. Hypocholesterolemic effect of yoghurt and milk
90. Studies of a surfactant and cholesterolemia in the Massai
91. The effect of skim milk, yoghurt and full cream milk on human serum lipids
92. The effect of fermented and unfermented milks on serum cholesterol
93. Lactobacillus effects on cholesterol in vitro and in vivo results
94. Properties of Lactobacillus caseii shirota strain as probiotics
95. Calcium, phosphorus, vitamin D, dairy products and colorectal carcinogenesis: A French case-control study
96. Prophylactic effect of Lactobacillus casei preparation on the recurrence of superficial bladder cancer
97. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double blind trial
98. Treatment of hepatic encephalopathy by alteration of intestinal flora with Lactobacillus acidophilus
99. Longterm effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy
100. Lactobacillus acidophilus in treatment of hepatic encephalopathy
101. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria
102. Probiotics in inflammatory bowel disease: New insight to pathogenesis or a possible therapeutic alternative?
103. The effect of exogenous administration of Lactobacillus reuteri R2LC and oat fiber on acetic acid-induced colitis in the rat
104. Continuous feeding of Lactobacillus plantarum attenuates established colitis in interleukin-10 deficient mice
105. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
106. Impact on the faecal flora composition of a new probiotic preparation. Preliminary data on maintenance treatment of patients with ulcerative colitis intolerant or allergic to 5-aminosalicylic acid
107. Maintenance treatment of chronic pouchitis: A randomized, placebo controlled, double-blind trial with a new probiotic preparation
108. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhoea-a pilot study
109. A double-blind trial of non-pathogenic E. coli vs mesalazine for the treatment of ulcerative colitis
110. Prevention par Saccharomyces boulardii des diarhées de l'alimentation enterale a debit continu
111. Efficacy of two antibiotics and a probiotic in the treatment of small intestinal bacterial overgrowth
112. In vitro Helicobacter pylori clearance failure with Lactobacillus acidophilus
113. Preservation of intestinal integrity during radiotherpy using live Lactobacillus acidophilus cultures
114. Probiotic therapy in Children with short bowel syndrome and bacterial overgrowth
115. Probiotics in the treatment of irritable bowel syndrome (IBS) - A randomised double blind placebo controlled crossover study
116. Complementary medicine in non-ulcer dyspepsia: Is alternative medicine a real alternative? A randomised placebo controlled double blind clinical trail with two probiotic agents
117. Safety of lactic acid bacteria and their occurrence in human clinical infections
118. Lactic acid bacteria and human clinical infection
119. The safety of commercial products with viable Lactobacillus strains
120. Efficacy of entericcoated protease in preventing attachment of enterotoxigenic Escherichia colt and diarrhoeal disease in the RITARD model
121. Pathogenic potential of lactobacilli
122. Saccharomyces cerevisiae infection in man
123. Invasive infection with Saccharomyces cerevisiae: Report of three cases and review
124. Saccharomyces cerevisiae septicaemia in a cancer patient
125. Saccharomyces cerevisiae infection in a patient with acquired immunodeficiency syndrome
126. Fungaemia with Saccharomyces boulardii in a 1 year old girl with protracted diarrhoea
127. Transfer of plasmid pAMbetal between members of the normal microflora inhabiting the murine digestive tract and modification of the plasmid in a Lactobacillus reuteri host
128. Ecological control of the gastrointestinal tract. The role of probiotic flora
129. Biotherapeutic agents: A neglected modality for the treatment and prevention of selected intestinal and vaginal infections